Foghorn Therapeutics announced it will not advance its FHD-909 and SMARCA2 degrader programs, ending collaboration with Lilly and cutting its workforce by 40%. Following this, its stock dropped over 30%. Pomerantz LLP is investigating whether Foghorn and its executives engaged in securities fraud or other unlawful practices. The investigation could impact investors as the company refocuses on other proprietary programs with long-term goals.
Foghorn Therapeutics faces a 40% workforce cut and halted drug programs amid a securities investigation. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 03:02 WIB: out of 128 priced US health stocks, 28 rose and 100 fell. Notable movers include VRTX at USD 485.08 (-4.32%), RXRX at USD 3.84 (-4.24%), and NBIX at USD 135.50 (-4.15%), with varied Pluang order activity and typical hold times.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
